Tia und nun ist es soweit #trml ist eingetroffen.
Erste Versuche sind auf dem Display

NOVARTIS OFFERS TO BUY TOURMALINE BIO AT $48/SHR IN CASH

#NVS #TRML

Most Searched, Tuesday September 9, 2025 – Crystal Equity Research

Most searched small-cap stocks, Tue Sept 9th - #ONDS #TRML #CIFR #IBRX #PL #OCTO #RZLV #HIVE #PTNM #VERI #CWD #UPXI #RR #STSS #SINT #QMMM #FTF #ESPR #CVI #AVXL - More: crystalequityresearch.com/most-searche... - #smallcap

Novartis to acquire Tourmaline Bio for $1.4 billion

#NVS #TRML

$1.4 Billion Deal: Novartis Acquires Tourmaline Bio's Breakthrough Anti-Inflammatory Heart Disease Drug Novartis to purchase Tourmaline Bio at $48/share, representing 59% premium. Deal adds pacibekitug anti-IL-6 antibody to cardiovascular portfolio. Closing expected Q4 2025.

#TRML Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG

www.stocktitan.net/news/TRML/tourmaline-bio...

First-Ever 85% CRP Reduction with Quarterly Dosing: Tourmaline's Breakthrough in Heart Disease Trial Biotech's pacibekitug achieves significant reductions in multiple cardiovascular biomarkers across all dosing arms. First IL-6 inhibitor showing deep CRP reductions with quarterly dosing.

#TRML Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress

www.stocktitan.net/news/TRML/tourmaline-bio...

Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights Tourmaline Bio (NASDAQ: TRML) reported Q2 2025 financial results and highlighted significant progress in its clinical programs. The company announced positive topline results from the Phase 2 TRANQUILITY trial of pacibekitug, demonstrating rapid and significant reductions in high-sensitivity C-reactive protein with quarterly dosing.Key financial metrics include cash position of $256.4 million as of June 30, 2025, providing runway into H2 2027. Q2 2025 saw net loss of $23.1 million ($0.90 per share), with R&D expenses at $19.6 million and G&A expenses at $6.3 million.The company plans to initiate a Phase 2 proof-of-concept trial in abdominal aortic aneurysm in H2 2025 and is preparing for a Phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease. Additional TRANQUILITY trial data will be presented at the upcoming European Society of Cardiology Congress.

#TRML Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/TRML/tourmaline-bio...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Mon Jun 2nd - #RMR #NKTR #LOGC #IMRX #HEPS #FTCI #DHAI #CLNN #BYRN #ACIC #XXII #AGM #CLBR #DOLE #ECC #FSLY #GUT #LSPD #OWLT #PINE #YALA #TRML - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights Tourmaline Bio (NASDAQ: TRML) reported Q1 2025 financial results and business updates. The company's Phase 2 TRANQUILITY trial for pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease is over-enrolled with 143 participants and remains on track for topline data in Q2 2025. The company ended Q1 with $275.3 million in cash, providing runway into H2 2027. Financial results showed R&D expenses of $20.3 million (up from $11.4M in Q1 2024) and a net loss of $23.0 million ($0.89 per share). The company is advancing pacibekitug for potential treatment of atherosclerotic cardiovascular disease (ASCVD) and abdominal aortic aneurysm (AAA), with plans to share additional development details alongside TRANQUILITY data. Their Phase 2b spiriTED trial for Thyroid Eye Disease continues with topline data expected in H2 2025.

#TRML Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/TRML/tourmaline-bio...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CSCO, #FLG, #BBAI, #TRML, #OWL

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#FLG, #TRML, #BITF, #CRNT, #BILL

#OptionFlow #OptionsTrading #Trading

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#PLTR, #BAC, #FLG, #ANET, #TRML

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #FLG 9.1x
2. #TRML 4.7x
3. #BITF 3.6x
4. #CRNT 3.2x
5. #PACK 2.5x

#OptionFlow #OptionsTrading #Trading

Tourmaline Bio Secures 2.5-Year Cash Runway with $294M, Accelerates Key Clinical Trials Biotech firm reports strong $294.9M cash position extending to 2027, over-enrolls Phase 2 TRANQUILITY trial with 143 patients. Key data readouts expected in 2025.

#TRML Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

www.stocktitan.net/news/TRML/tourmaline-bio...

Tourmaline Bio's TRANQUILITY Trial Surpasses Enrollment Target, Expands into Aortic Aneurysm Treatment Tourmaline Bio strengthens cardiovascular program with 143-patient TRANQUILITY trial milestone and new AAA indication. Notable scientific board appointments boost development strategy.

#TRML Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day

#stocks #investing #StockMarket

www.stocktitan.net/news/TRML/tourmaline-bio...

NEWS: ( NASDAQ: #TRML ) Outperform Recommendation Issued On TRML By BMO Capital

#StockMarket #News

News; ( NASDAQ: #TRML ) TRML Price Target Alert: $50.00. Issued by BMO Capital

#StockMarket #News

#TRML Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

www.stocktitan.net/news/TRML/tourmaline-bio...